also showed increased DNMT3A levels in MM patients compared to healthy controls and a trend to increased DNMT3A levels in ND and relapsed MM patients (the active phase of MM) compared to those in remission, thus showing its potential as a biomarker of MM progression (Table 2) (88). Here, DNMT3A is linked to Miyoshi myopathy.